Video Library
Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases
In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.
Prof. Deepak L. Bhatt
First published: September 10, 2024
Running time: 58 minutes, 46 seconds
01.28 Concept of cumulated LDL exposure (mg-years)
05.11 Re-defining secondary prevention
08.04 Early secondary prevention
11.27 Late secondary prevention (CHD)
19.17 Late secondary prevention (PAD)
20.15 Very late secondary prevention (ACS)
23.18 Longer is better
24.55 Earlier is better
26.21 Younger is better
28.39 Older Adults also deserve treatment
41.12 Audience Q&A
Video Library
“Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?
Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.
First published: October 25, 2023
Running time: 35 minutes, 49 seconds
00.00 Patients and plaque
03.30 Pictorial representation and
primary prevention or adherence07.00 Calcium Scoring
13.00 Other targets: Lp(a)
21.00 Triglycerides
28.00 Special: Latest data from ESC
Video Library
ASCVD Roundtable Part 2: Other targets and ESC 2023 Highlights
In this second part of the Round Table conversation, the Editorial Panel discuss how showing patients’ images of their plaques help with adherence, discuss other targets such as Lp (a) and triglycerides and most importantly, discuss some of the latest data from the recently concluded ESC congress.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: September 1, 2023
Running time: 25 minutes, 25 seconds
00.00 Introduction
01.21 LDL target and guidelines
07.55 Should we start combination
therapy early?12.35 Side effects of combination
therapy?16.40 Dosing in combination
therapy – InclisiranVideo Library
ASCVD Roundtable Part 1: Target guidelines, dosing, and compliance in lipid lowering therapies
In recognition of the ASCVD & Lipidology Knowledge Hub 2 year anniversary, the esteemed faculty members for this educational resource site met to discuss the hot topics that have occurred over this time. Come and take a seat at this roundtable discussion with Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, and Prof. Deepak Bhatt as they discuss target guidelines, dosing, and compliance in lipid lowering therapies.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: August 1, 2023
Video Library
Acute Coronary Syndrome Secondary Prevention – never too early, always too late
In this KOL master class on demand video Prof. Samer Ellahham discusses the secondary prevention of acute coronary syndrome (ACS). He is joined by Prof. Hani Sabbour for a peer-to-peer discussion and to answer audience questions.
This interactive webinar is designed for health care professionals (cardiologists, endocrinologists, lipidologists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with acute coronary syndrome.
Prof. Samer Ellahham, Prof. Hani Sabbour
First published: February 28, 2023
Video Library
ESC Congress 2022 Highlights – Part One
Watch part one of the ESC Highlights Video. In this video Prof. Lale Tokgözoğlu summarizes some of the exciting findings that were presented in ESC 2022.
Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu
First published: November 1, 2022
Video Library
ESC Congress 2022 Highlights – Peer-to-Peer Discussion – Part Two
Watch part two of the ESC Highlights Video wherein Prof. Christopher Cannon and Prof. Lale Tokgözoğlu discuss results of some exciting trials highlighting the significance of Lp(a), PCSK9 inhibitors, patient adherence and compliance.
Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu
First published: November 1, 2022
Video Library
Impact of lipid therapies on coronary disease
In this KOL masterclass on demand video, Prof. Stephen Nicholls will discuss the impact of intensive lipid lowering strategies (statins, evolocumab, alirocumab) on plaque phenotype and progression.
This masterclass on-demand video is designed for health care professionals (cardiologists, lipidologists, diabetes specialists, neurologists) who are interested in learning more on the results of the latest clinical trials (GLAGOV, HUYGENS, PACMAN-AMI) on coronary disease.
Prof. Stephen Nicholls
First published: July 7, 2022
Video Library
Peer-to-Peer Discussion: Novel lipid-lowering therapies
Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.
To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.
Prof. Christopher Cannon, Prof. Kausik Ray
First published: January 10, 2022
1 2